Weekly Recap | BioNTech SE -0.75%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.The Week
BioNTech (BNTX) fell 0.75% this week to $87.51, outperforming the S&P 500 by roughly 1.93 percentage points. The trend was a rise-then-fade: Monday opened at $88.20, Wednesday pushed as high as $91.46, then gave ground on Thursday to $85.80 before ticking up to Friday’s close of $87.51. Friday’s intraday low of $84.89 also marked the bottom of the last 60 sessions.
Key Events
Q3 results and a buy-back dominated the week. Before Tuesday’s open, BioNTech reported Q3 revenue of €1.2892 billion and net profit of €184.5 million, swinging back to profitability, while lifting the midpoint of FY2026 revenue guidance to €1.7–1.9 billion. The company also unveiled a share buy-back programme of up to $1 billion in ADS by May 2027. The ADR rose 3.3% on Tuesday and added more than 3% intraday Wednesday, before Thursday and Friday saw the gains unwind, at one point down nearly 4%. FactSet’s FY2026 loss-per-share estimates were first revised up and later down, with the target price moving from $100.19 to $107.02.
Analyst Ratings
As of 4 November, 21 brokers cover BioNTech: 13 rate it buy, 1 overweight and 7 hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target of $115.27, about 32% above spot. Individual targets range from $75.95 to $144.10, showing wide dispersion. Within biotech, the rating rank is 27th out of 510 names.
The Week Ahead
Next week’s macro calendar is heavy: US CPI and core CPI land on 10 November, with market forecasts diverging from prior prints and likely to influence how risk assets are priced. On the company front, BioNTech’s next update is its Q4 FY2026 results on 2 March 2027 pre-market, with consensus at a $1.5867 loss per share and €539 million in revenue. No immediate earnings overhang sits in the near term.
In Short
A strong Q3, raised guidance and a new buy-back did not translate into a one-way move: the stock faded after Wednesday’s high, though it still beat the S&P 500 by about 1.93 percentage points this week. The consensus rating stays at buy and the consensus target sits above spot, but the target range spans nearly $68, pointing to wide disagreement. The latest session’s money flow shows no net large-lot inflow and a net-seller skew across smaller orders. What to watch next: how the stock handles post-CPI repricing, and how quickly the $1 billion buy-back is actually executed.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.